General Information of the Drug (ID: M6APDG03099)
Name
octanol
Synonyms
1-octanol; Octan-1-ol; octanol; 111-87-5; N-octanol; Capryl alcohol; Octyl alcohol; caprylic alcohol; n-Octyl alcohol; Heptyl carbinol; 1-Hydroxyoctane; Primary octyl alcohol; Alcohol C-8; n-Octan-1-ol; Octilin; Sipol L8; Alfol 8; Lorol 20; Dytol M-83; n-Caprylic alcohol; 1-Octyl alcohol; n-Heptyl carbinol; EPAL 8; octyl-alcohol; Alcohols, C6-12; N-octyl-alcohol; Octyl alcohol, normal-primary; C8 alcohol; Fatty alcohol(C8); Octyl alcohol, primary; Caswell No. 611A; Octyl alcohol (natural); FEMA Number 2800; Lorol C 8-98; n-Capryl alcohol
    Click to Show/Hide
Status
Investigative
Structure
Formula
C8H18O
InChI
1S/C8H18O/c1-2-3-4-5-6-7-8-9/h9H,2-8H2,1H3
InChIKey
KBPLFHHGFOOTCA-UHFFFAOYSA-N
PubChem CID
957
TTD Drug ID
D00VJY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Gap junction alpha-1 protein (GJA1)
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
Response Summary Gap junction alpha-1 protein (GJA1) is a therapeutic target for octanol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of octanol through regulating the expression of Gap junction alpha-1 protein (GJA1). [1], [2]
References
Ref 1 YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell. 2020 Dec 14;38(6):857-871.e7. doi: 10.1016/j.ccell.2020.10.004. Epub 2020 Oct 29.
Ref 2 Clinical pipeline report, company report or official report of OcuNexus Therapeutics.